Zimmer boosts biologics with ETEX buy
This article was originally published in Clinica
Executive Summary
Orthopedic firm Zimmer has bolstered its biologics portfolio by acquiring ETEX Holdings for an undisclosed fee. The Cambridge, Massachusetts firm has several bone void filler products including the injectable Beta-bsm, Gamma-bsm putty, CarriGen and EquivaBone. Zimmer’s existing biologics offering includes Gel-One, an injectable hyaluronate gel approved for the treatment of osteoarthritis of the knee; Chondrofix, an osteochondral allograft for osteochondral lesions in the ankle; and the Denovo NT juvenile cartilage implant for the repair of articular cartilage damage. “ETEX's innovative bone substitute material products add more depth to a growing portfolio of solutions for the early stages of joint disease," stated Joseph Cucolo, president of Zimmer Americas. The purchase is Zimmer’s second this year: in April, it splashed out $13.35bn on Biomet, propelling it to the number-two position in the overall orthopedic market.